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Abstract
Background: Proper wound healing after regenerative surgical procedures is an essential issue for clinical success.
Guided tissue regeneration (GTR) and application of enamel matrix derivatives (EMD) are common means to regenerate
periodontal tissues. Both methods bear considerable advantages due to their special characteristics, but also go along
with certain disadvantages. Today, there is no consensus in the literature whether GTR or EMD show better results
regarding early wound healing, which is considered a crucial stage in periodontal regeneration. Therefore, the aim of the
present systematic review was to compare the early wound healing after regenerative periodontal surgery with either
EMD or GTR treatment.
Methods: An electronic literature search in PubMed was performed to identify randomized clinical trials (RCTs) or clinical
trials (CTs) comparing regenerative surgery employing EMD and/or GTR in patients with chronic periodontitis. Among the
finally included studies, a qualitative and quantitative data extraction regarding early wound healing parameters was
performed. Primary outcome parameters were early wound healing index (EWH), flap dehiscence, membrane exposure,
suppuration and abscess formation during the first 6 weeks. As secondary parameters, swelling and allergic reactions
were assessed.
Results: Seven studies reporting 220 intrabony periodontal defects in 199 patients were analysed.
Flap dehiscence was observed in two studies in 12% of the GTR treated sites and in 10.3% of those treated with EMD.
Membrane exposure was evaluated in five studies and was registered in the 28.8% of the defects, while no dehiscence
was reported on the EMD group. Swelling was reported only in one study in 8/16 GTR sites and 7/16 EMD sites. Due to
considerable heterogeneity of parameters no meta-analysis was possible.
Conclusions: Due to considerable heterogeneity of the published studies a clear beneficial effect of the EMD on the
early wound healing outcomes after surgical treatment of periodontal intrabony defects cannot be confirmed.
Standardized RCT studies are needed in order to allow for proper comparison of early wound healing after both types
of surgical approaches.
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Background
The World Workshop of the Classification of Periodontal
and Peri-Implant Diseases and Conditions of 2017 defines
periodontitis as a chronic multifactorial inflammatory dis-
ease associated with dysbiotic plaque biofilms and charac-
terized by progressive destruction of the tooth-supporting
apparatus [1].
Treatment of periodontitis aims on one hand at prevent-
ing further disease progression by minimizing inflammation
by active therapy and – on the other hand - at supporting
patients in maintaining a healthy periodontium [2].
The management of chronic periodontal disease requires
a combination of different therapeutic steps. In first place, a
non-surgical approach that includes oral hygiene instruc-
tions [3], control of local [4] and systemic factors [5] like
the adjustment of excessive forces on single teeth [6] or an
untreated diabetes mellitus [7], respectively. Then, supra
and subgingival instrumentation is performed as the core
step in order to mechanically remove biofilms and mineral-
ized deposits [8, 9]. The latter may be supported by
topically or systemically applied pharmacotherapy [10]. In
second place, after an adequate healing period, surgical ap-
proaches may be indicated to eliminate residual pockets
and to create a gingival morphology that allows for efficient
plaque control [2]. Likewise, lost tissues might get regener-
ated by special surgical methods if anatomy and patient
characteristics allow for it [11]. It is the aim of such
interventions to rebuild each of the tooth-supporting
structures, including root cementum, periodontal
ligament, and alveolar bone, that were lost due to
periodontal inflammation [12, 13].
True regeneration has scientifically been proven espe-
cially after conventional guided tissue regeneration (GTR)
[14] or the use of enamel matrix derivatives (EMD) [15].
The principles of GTR are based on the exclusion of the
proliferating epithelium during the first phase of wound
healing. Using a cell-dense membrane, space is provided
for slow-proliferating bone and root cementum [14]. On
the other hand, EMD, consisting of a heterogeneous mix-
ture of porcine amelogenines, and propylene glycol algin-
ate (PGA) as carrier allows for a pharmacologically
induced regeneration of periodontal tissues [16, 17].
Especially in regenerative surgical procedures, early and
safe wound closure is a crucial factor for success [18]. This
depends on the maintenance of wound stability in the first
post-surgical weeks [19, 20]. Particularly, the critical signifi-
cance of primary intention healing for periodontal regener-
ation has been demonstrated in a retrospective study on
GTR procedures by Trombelli et al. showing significant
lower values of bone level gain when the membrane got
previously exposed [21].
Several surrogate parameters are used to describe early
wound healing in oral soft tissues. Special scores for
early periodontal wounds have been proposed in order
to comprehensively describe healing by numerous surrogate
parameters like tissue colour, bleeding, characteristics of inci-
sion margins and presence of suppuration [22], assessment
of wound closure, abscess formation, fibrin and necrosis [23]
and, furthermore, edema, erythema, suppuration, patient dis-
comfort and flap dehiscence [24]. Recently, the Early Wound
Healing Score (EHS) was introduced to assess wound healing
by primary intention 24 h post-surgery through the evalu-
ation of clinical signs of re-epithelialization, haemostasis and
inflammation [25]. However, most clinical studies report
early complications reflecting on wound dehiscence and
post-operative pain only [26, 27].
Success of regenerative therapy, however, is multi-fac-
torial and depends on numerous aspects. The placement
of membranes has - besides the intended beneficial impact
- a potential side effect that can hamper the surgical out-
come [28–30]. Since the cell-dense membrane does not
only hamper cell migration but also diffusion, the
nutrition of the gingival tissues is limited and may tend to
result in wound dehiscence and membrane exposure. As a
consequence, membrane surfaces get colonized by oral
biofilm which, in turn, leads to further inflammation, jeop-
ardizing the success of the surgical procedure [29, 30].
The use of EMD on the other hand, has been de-
scribed to have a positive effect on early wound healing.
Specifically, EMD has been shown to accelerate
reepithelialization, wound closure, resolution of inflam-
mation and prolonged blood vessels formation [31–33].
Indeed, in some studies more post-surgical complica-
tions following GTR than after EMD application have
been reported [15, 28] whereas others found no differ-
ences in the healing process [26, 27].
So far there is no consensus whether the use of EMD
may show better early wound healing as compared to GTR.
Therefore, this systematic review aimed at comparing
early wound healing after regenerative periodontal
surgery with GTR or EMD application. Our hypothesis
was that there is beneficial effect of the EMD when
compared to GTR on the early wound healing after sur-
gical treatment of periodontal intrabony defects.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was consulted
to the process of the present systematic review.
Focused question
In periodontal defects, are the early wound healing out-
comes after periodontal regenerative surgery better after
the use of EMD as compared to GTR?
Eligibility criteria
The studies were selected according to the following
criteria:
Rojas et al. BMC Oral Health           (2019) 19:76 Page 2 of 16
Inclusion criteria
 Randomized Clinical Trials (RCTs) or Clinical Trials
(CTs) comparing surgical regenerative interventions
using Enamel Matrix Derivatives or Membranes,
both in combination or without bone substitutes in
the surgical treatment of intrabony periodontal
defects or furcation involvement defects;
 Human adults (> 30 years) with chronic periodontitis
and good general health status;
 Non-smoker patients;
 Generally healthy patients.
Exclusion criteria
 Non adult patients;
 Systemic diseases;
 Patients with aggressive periodontitis;
 Smokers
The outcome was assessed in terms of early wound
healing during the time period of one to six weeks. Pri-
mary outcome parameters were early wound healing
index (EWH), flap dehiscence, membrane exposure (in
GTR group), suppuration and abscess. As secondary pa-
rameters, swelling and allergic reactions were used.
Search strategy
A comprehensive and systematic electronic search of US
National Library of Medicine (Pubmed) was performed.
The search was conducted for trials in the period up to
July 2018. The following key words were used: (guided
tissue regeneration OR regenerative OR Emdogain OR
enamel matrix derivatives OR amelogenin OR mem-
brane) AND (periodontitis OR periodontal therapy OR
periodontal surgery) AND (RCT OR clinical trial).
The literature research was performed without lan-
guage restrictions.
Selection of the studies
Previous to the screening process, the first 50 titles and
abstracts were used to calibrate the two reviewers (MR
and LM) with a senior researcher (PS). Consequently,
two reviewers (MR and LM) screened independently all
titles and abstracts. Then, studies potentially complying
with the inclusion criteria were selected for full text as-
sessment. After independent assessment, any disagree-
ment between both reviewers was resolved by discussion
with a third reviewer (PS).
Data extraction
Relevant data, including population characteristics,
intervention sites characteristics, description of the treat-
ment prior to and at completion of the interventions,
post-surgical indications and medications, time of the
study, maintenance therapy characteristics and early
wound healing parameters assessed were independently
extracted by two reviewers (MR and LM).
Quality assessment of included studies
Following the guidelines of the Cochrane Collaboration
[34] a quality assessment of the included studies was
performed independently by MR and LM.
Therefore, six domains were evaluated: 1) sequence
generation, 2) allocation concealment, 3) blinding of par-
ticipants and outcome assessors, 4) incomplete outcome
data, 5) selective outcome reporting, 6) other sources of
bias. In each assessment tool previously mentioned, a
judgement of “Yes” or “No” indicated low and high risk
of bias, respectively; whereas “Unclear” judgement indi-
cated uncertain risk of bias.
A study was assigned as “Low risk of bias” when all the
domains were of low risk of bias. However, when one or
more key domains resulted with unclear or high risk of bias,
the study was assigned as “Unclear or High risk of bias”.
The quality of non-randomized clinical trials was assessed
using the Cochrane Collaboration tool -ROBINS-I tool-
(“Risk Of Bias In Non-randomized Studies - of Interven-
tions”) [35, 36]. Seven domains were evaluated: pre-inter-
vention: 1) bias due to confounding, 2) bias in selection of
participants into the study; at intervention: 3) bias in classi-
fication of interventions; post- intervention: 4) bias due to
deviations from intended interventions, 5) bias due to miss-
ing data, 6) bias in measurement of outcomes, 7) bias in se-
lection of the reported result. The bias of the studies was
assigned as follows:
“Low risk of bias”: all key domains were of low risk of
bias;
“Moderate risk of bias”: low or moderate risk of bias
for all the domains, and moderate risk of bias in any
domain;
“Serious risk of bias”: at least one domain with serious risk
of bias but not any critical risk of bias in any domain;
“Critical risk of bias”: at least one domain with serious
critical of bias.
Any disagreement for data extraction and quality as-
sessment was discussed and resolved by consensus. A
third reviewer (PS) was consulted when necessary.
Results
Search and screening
The search strategy generated 968 potentially fitting arti-
cles. After title and abstract screening, 26 articles were
eligible for possible inclusion (Fig. 1). During full-text
assessment, nineteen articles were excluded due to
smoking (nine articles) [37–45], patients younger than
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30 years of age (three studies) [46–48], diagnosis of aggres-
sive periodontitis (two studies) [49, 50], missing outcomes
for early wound healing evaluation (one study) [51] and
not-fitting treatments group (one study) [52]. Moreover,
three studies [53–55] were found to report long-term
results of already included publications and were likewise
excluded. Finally, seven studies were included [56–62]. Re-
viewer agreement for title and abstract screening was 92%
and agreement for the full text screening before discussion
was 88%(Table 1).
Data analysis
To assess and detect similarities and differences between
the studies - and to determine if it was possible to perform
a further synthesis or comparison methods - data were
summarized into evidence tables and a summary was
performed.
Considerable heterogeneity was found in the studies, re-
garding the whole range of assessed parameters, including
different follow-up time period evaluation, study design
and specific GTR treatment. Moreover, the morphologic
baseline characteristics of the surgical sites showed strong
heterogeneity between groups of different studies, or it
was often not reported. For this reason, it was not possible
to conduct a reasonable data synthesis for the included
studies and a meta-analysis could not be performed.
Quality assessment and risk of bias assessment of
selected publications
Six studies [56, 58–62] were randomized trials. According
to the guidelines of the Cochrane Collaboration [34], three
studies showed a high risk of bias [59, 60, 62] and three
studies an unclear risk of bias [56, 58, 61] (Table 2).
One study [57] was reported as a non-randomized clin-
ical trial (a case-cohort study) and according to Cochrane
Collaboration tool -ROBINS-I tool [35, 36], resulted to be
a low risk of bias (Table 3).
Description of the studies
Study characteristics
The characteristics of the studies are described in Table 4.
Four of the seven studies included in the present re-
view were parallel (double-arm) studies [58–61], two
Fig. 1 Flow diagram (PRISMA format) of the screening and selection process
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[57, 62] were identified as multi-arm studies and one
was designed as a split-mouth study [56].
A power calculation was performed in two of the
seven studies [58, 59]. One study [57] was conducted in
a private practice and the other six [56, 58–62] in uni-
versity settings.
Regarding the funding sources, no according infor-
mation was given in three of the studies [56, 59, 60].
For two of the studies [58, 61] no financial or mater-
ial support was provided by any company. One study
[62] reported industrial funding sources (Biora,
Sweden and WL Gore). One other [57] was partly
supported by scientific organizations (Accademia To-
scana di Ricerca Odontostomatologica, Florence, Italy
and the Periodontal Research fund of the Department
of Periodontology of the Eastman Dental Institute,
London U.K).
Five studies were double-blinded [56, 58, 60–62], while
one was single-blinded [59] and in one study [57] no
masking was performed.
Six different types of GTR techniques were compared
with EMD: in four studies a bioabsorbable membrane
was used [56, 57, 60, 62]. In two studies [57, 58] an
expanded polytetrafluoroethylene (e-PTFE) membrane
with titanium reinforcement, and in one study [58] with-
out titanium reinforcement were used, while in two
other studies the combination of a bioabsorbable mem-
brane and bone graft [57] or bioabsorbable membrane
and EMD [62] were selected. In one of the studies [59]
EMD was not used as sole application but combined
with deproteinized bovine bone mineral (DBBM) and
compared with a control group, which employed DBBM
and a collagen membrane [59]. Follow-up periods were
reported at 6 months for one study [60], 8 months for
Table 1 Excluded studies
Reference Rationale for exclusion
Zucchelli G, Bernardi F, Montebugnoli L,De SM [37]. Smoker patients included (< 20 cigarettes/day)
Windisch P, Sculean A, Klein F, et al. [38]. Smoker patients included
Sculean A, Windisch P, Chiantella GC, et al. [45]. Smoker patients included
Minabe M, Kodama T, Kogou T, et al. [39]. Smoker patients included (< 10 cigarettes/day)
Meyle J, Gonzales JR, Bödeker RH, et al. [40]. Smoker patients included (< 20 cigarettes/day)
Sanz M, Tonetti MS, Zabalegui I, et al. [41]. Smoker patients included (< 20 cigarettes/day)
Parashis A, Andronikaki-Faldami A, Tsiklakis K [42]. Smokers patients included
Jepsen J, Heinz BB, Jepse Kn, et al. [43]. Smoker patients included (< 20 cigarettes/day)
Hoffmann T, Richter S, Meyle J, et al. [44]. Smoker patients included (< 20 cigarettes/day)
Röllke L, Schacher B, Wohlfeil M, et al. [46]. Patients > 18 years included
Silvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V. [47]. Patients > 21 years included
Silvestri M, Sartori S, Rasperini G, et al. [48]. Patients > 21 years included
Farina R, Simonelli A, Rizzi A, et al. [49]. Chronic or aggressive periodontitis patients included
Ghezzi C, Ferrantino L, Bernardini L, Lencioni M, Masiero S. [50]. Chronic or aggressive periodontitis patients included
Pontoriero R, Wennström J, Lindhe J. [51] Outcomes not reported in terms of early wound healing
Jaiswal R, Deo V. [52] No intervention treatment (EMD) present
Sculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M. [55] Report long-term data of a previous included study [56]
Sculean A, Schwarz F, Miliauskaite A, et al. [53]. Report long-term data of a previous included study [56]
Sculean A, Donos N, Schwarz F, et al. [54]. Report long-term data of a previous included study [45]
Table 2 Summary of risk of bias of included RCTs
Domains Adequate sequence
generation?
Allocation
concealment?
Blinding? Incomplete outcome
data addressed?
Free of selective
reporting?
Free of other
bias?
A.Sculean et al. 1999a [56] Yes Yes Yes Yes Unclear Unclear
A.Sculean et al. 1999b [60] Unclear Unclear Yes Yes Unclear No
N. Donos et al. 2004 [62] Yes Yes Unclear Yes Unclear No
A.Crea et al. 2008 [61] Yes Yes Yes Yes Unclear Yes
V. Iorio-Siciliano et al. 2011 [58] Yes Yes Yes Yes Unclear Yes
V. Iorio-Siciliano et al. 2014 [59] Yes Yes No Yes Unclear No
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one study [56], 12 months for four studies [57–59, 62]
and 36months for one study [61].
Population characteristics
Patient’s characteristics A total of 199 patients with an
age range between 30 and 73 years were assessed in the
included studies. Two studies not reported the age of
the patients [56, 60] and two studies not reported the
gender [60, 62]. All patients enrolled in the studies [57–
62] were explicitly reported to suffer from chronic peri-
odontitis while in one study [56] the diagnosis was dir-
ectly confirmed by the corresponding author to be
chronic periodontitis (Table 5).
Teeth and defect characteristics at baseline The stud-
ies reported 220 teeth with different intrabony and fur-
cation defects (one defect per tooth); 97 defects were
treated with EMD and 123 defects with GTR technique.
In one study [62], degree III furcation-involved defects in
mandibular molars were treated. In another study [61]
3-wall, angular intrabony defects in the interproximal area
with an intrabony component ≥4mm (measured from the
crest to the deepest part of the bony defect) were selected.
In one of the studies 2 to 3-wall defects were used [56]
while in another [60] advanced intrabony defects (teeth
scheduled for extraction) were treated.
Non-contained combined osseous defects in the inter-
proximal area with an intrabony component ≥3mm were
treated in two of the studies [58, 59]. Finally, in one of the
studies [57] different types of intrabony defects (1, 2 and 3
walls) were included and the treatment was assigned ac-
cordingly: 1-wall intrabony component 1–3mm defects
were treated with GTR with e-PTFE titanium reinforced
membrane (TrM), 1-wall intrabony component 1–5mm
were treated with GTR (BM+ BG) whereas in 2 to 3-wall
narrow defects only MB was used. EMD was applied in
the defects with a prevalent 3-wall component.
In one study the selected teeth were scheduled for ex-
traction for periodontal or prosthetic reasons [60]. Two
studies treated anterior and posterior teeth without fur-
cation involvement [59, 61] whereas in another study
[58] only single-rooted teeth including maxillary first
premolars were selected. In two studies [56, 57] the type
of tooth selected was not available (Table 5).
Treatment characteristics and early wound healing
parameters assessed
Table 6 describes the main characteristics of the selected
studies.
Treatment prior to the intervention In all the studies
non-surgical periodontal therapy was performed. In four
of them the pre-treatment initiated 3 months before sur-
gery [56, 60–62], in the others no such time period was
reported. In one study [60] - in which teeth scheduled
for later extraction were selected as surgical sites - teeth
were splinted before to reduce the mobility. One investi-
gation also reported that non study-specific flap surgery
was performed also in the dentition [57].
Table 3 Summary of risk of bias of non-randomized clinical trial
Domains Due to
confounding
Selection of
participants
Classification
of interventions
Deviations from
intended interventions
Missing
data
Measurements
of outcomes
Selection of the
reported results
P. Cortellini et al. 2005 [57] Low Low Low Low Low Low Low
Table 4 Characteristics of included studies
Author, year
of publication
Study design Power
calculation
Setting Funding
sources
Masking Intervention Follow-up
A.Sculean et al. 1999a [56] RCT Split-mouth No U Not specified Double-blind EMD vs BM 8 mo
A.Sculean et al. 1999b [60] RCT Double-arm No U Not specified Double-blind EMD vs BM 6 mo
N. Donos et al. 2004 [62] RCT Multi-arm Three groups No U Yes Double-blind EMD vs BM
vs EMD + BM
12 mo
P. Cortellini et al. 2005 [57] Non-RCT Case-cohort study Multi-
arm Four groups
No PP Yes Not
performed
EMD vs BM
vs BM + BG
vs e-PTFE TrM
12 mo
A. Crea et al. 2008 [61] RCT Double-arm No U No Double-blind EMD vs e-PTFE
M
36 mo
V. Iorio-Siciliano et al. 2011 [58] RCT Double-arm Yes U No Double-blind EMD vs e-PTFE
TrM
12 mo
V. Iorio-Siciliano et al. 2014 [59] RCT Double-arm Yes U Not specified Single-blind EMD + DBBM
vs BM + DBBM
12 mo
BG bone graft, BM bioabsorbable membrane, DBBM deproteinized bovine bone mineral, EMD enamel matrix derivative, e-PTFE expanded polytetrafluoroethylene;
mo months, M membrane, PP private practice, RCT randomized clinical trial, TrM titanium reinforced membrane, U university
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Intervention and specific treatment The surgical
procedures were similar in all the studies. The main
difference was found to be the design of the incision.
Local anaesthesia, full flap elevation, granulation tissue
removal and scaling and root planing were described as
common steps in all the studies. In three studies, intra-
crevicular incisions were performed [56, 60, 62] whereas
in other three the simplified papilla preservation flap
(SPPF) or modified papilla preservation flap (MPPT)
[57–59] were selected according to the surgical site
characteristics. In one of them [61] only SPPF was used.
The specific treatment on the EMD group consisted of
a 2-min application of 24% EDTA gel and the applica-
tion of EMD after careful rinsing for all studies. In one
study EMD was combined with DBBM [59].
Regarding the specific treatment on the GTR group, in
five of them a bioabsorbable membrane was used either
alone [56, 57, 60, 62] or combined with EMD [62] or bone
graft [57, 59]. In three studies [57, 58, 61] e-PTFE mem-
brane was selected, in two of them with titanium
reinforcement [57, 58].
In all studies non-resorbable suture materials were
used (e-PTFE sutures were reported in four studies) [57,
60–62] except in one study [56] in which this data was
not available. The time of suture removal was 14 days
for three studies [56, 60, 62] and between 7 and 10 days
for the rest of the studies [57–59, 61].
Post-surgical medication and maintenance The post-
surgical medication was different for all the studies. In
three of them [56, 60, 61] amoxicillin was selected but the
prescription was diverse, and in one of them was com-
bined with metronidazole [56]. In one study [62] only
metronidazole was indicated and in other doxycycline
[57]. In two studies [58, 59] only anti-inflammatory drugs
were used (ibuprofen or acetaminophen).
The antibiotic period of administration was between 1
week and 10 days and the anti-inflammatory drugs were
indicated only the day of the surgical procedure.
Post-surgical chlorhexidine (CHX) was indicated in all
the studies. In five studies 0.12% CHX was used for 2
[58, 59] and 6 weeks [56, 57, 60]. In one study [62] 0,2%
CHX was indicated and also was complemented with
weekly professional local irrigations for the first
post-surgical 6 weeks. Finally, in one study [61] 1% CHX
gel for 4 weeks was selected.
Table 5 Population characteristics
Author, year
of publication
Patient’s characteristics Teeth and defect characteristics at baseline
Number
of patients
Gender
(m/f)
Mean age/
Range (years)
Type of
periodontitis
Drop-out Number/Type
of tooth
Number/Type
of defects
A.Sculean et al.
1999a [56]
16 10 m/6f NA
NA
chronic
periodontitisa
0 32
NA
32
2 to 3-wall intrabony defects
A.Sculean et al.
1999b [60]
14 NA NA
NA
chronic
periodontitis
0 14
teeth scheduled
for extraction
14
advanced intrabony defects
(teeth scheduled for extraction)
N. Donos et al.
2004 [62]
9 NA NA
40–73
chronic
periodontitis
0 14 (EMD 4; GTR 3;
EMD + GTR 7)
mandibular molars
14
degree III furcation-involved defects
P. Cortellini et al.
2005 [57]
40 17 m/23f 41.3 ± 10.7
NA
chronic
periodontitis
0 40
(e-PTFE TrM 12;
BM + BG 11;
BM 7;
EMD 10)
NA
40
intrabony defects
1-wall
1-wall
2 to 3-wall
3-wall
A. Crea et al. 2008
[61]
40 19 m/21f 45.8
35–66
chronic
periodontitis
1 40 (39 evaluable)
anterior/posterior
40 (39 evaluable) 3-wall intrabony
defects
V. Iorio-Siciliano
et al. 2011 [58]
40 19 m/21f NA
39–52
chronic
periodontitis
0 40
single-rooted teeth
40
non- contained intrabony defects
combination
≥80% 1-wall component (2 to 3-wall
component in the most apical part)
V. Iorio-Siciliano
et al. 2014 [59]
40 18 m/22f 44.4
33–57
chronic
periodontitis
0 40
single- and multi-rooted
teeth
40
non- contained intrabony defects
combination
≥70% 1-wall component (2 to 3-wall
component in the most apical part)
BG bone graft, BM bioabsorbable membrane, EMD enamel matrix derivative, e-PTFE expanded polytetrafluoroethylene, f female, GTR guided tissue regeneration, m
male, NA not available, PD probing depth, TrM titanium reinforced membrane
aconfirmed by the author (A.S)
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The maintenance period was similar in three studies
in which recall visits were performed each 1 week for
the first 6 weeks and then once a month [57, 62] or
every 3 months [61]. In two studies [58, 59] the profes-
sional maintenance care was performed at 2 and 4 weeks
and each 3months afterwards. In two studies visits were
scheduled every 2 weeks for all the follow-up time [60]
or for the first 2 months and once a month afterwards
[56]. The period necessary to resume oral hygiene proce-
dures was also reported: in 3 studies [56, 60, 61] normal
hygiene was initiated after 6 weeks, in two studies [58,
59] modified oral hygiene procedures were indicated for
the first 4 weeks and in one study [57] was resumed 2–4
weeks after removal of the non resorbable membrane or
after 4 weeks when resorbable membrane or EMD were
used. In one study [61] this data was not clear.
Periodontal surrogate parameters Clinical attachment
level (CAL), probing depth (PD) and gingival recession
(GR) were evaluated in all of the studies except in one of
them [62]. Bleeding on probing (BOP) was evaluated in
four of the studies [56, 57, 61, 62] whereas in three studies
[57–59] full mouth plaque score (FMPS) and full mouth
bleeding score (FMBS) were registered. Gingival index
(GI) was registered in one study [56], and plaque index
(PI) also was measured in only one study [61].
Intra-surgical and radiographic measurements of the
defects were performed in three studies [58, 59, 61].
Early wound healing parameters assessed No study
reported data on EWH. Membrane exposure was evalu-
ated in five studies [56, 58–60, 62]; in one study [56] this
evaluation was performed at 3 weeks, in two studies at 1
week [58, 59], in one study [62] during the first 2 weeks
whereas in one study [60] the evaluation time was not
available.
Wound dehiscence was registered in two studies at the
first week [61] or every week for the first 6 weeks [57].
Abscess formation was registered in four studies [56,
60–62], in two of them at the first week [56, 61]. The
time was not reported for the other two studies [60, 62].
Suppuration was evaluated only in two studies [56,
60]. Pain/discomfort was registered by only one study
[61] in the first 5–6 days.
Allergic reaction was evaluated in four studies [56, 60–
62] and swelling was evaluated in two of them [56, 61].
Early wound healing outcomes
Table 7 illustrates the early wound healing outcomes of
the seven included studies.
Flap dehiscence was evaluated in two studies [57, 61]
and 79 sites. Dehiscences were observed in 6/50 (12%)
of the GTR treated sites and in 3/29 (10.3%) of the EMD
treated sites. Membrane exposure was evaluated in five
studies [56, 58–60, 62] and was registered in 21/73
(28.8%) of the defects. In one of these studies [56], in
which 7 of the 16 (43.7%) of the GTR treated defects
showed exposition of the membrane at 3 weeks, swelling
also was observed in 8 of the 16 sites at the first
post-surgical week. Flap dehiscence, however, was not
registered in sites treated with EMD while swelling were
found in the same number of cases.
When flap dehiscence and membrane exposure were
evaluated together it was observed that flap dehiscence
Table 7 Early wound healing outcomes
Author, year
of publication
Primary outcomes Secondary outcomes
Flap dehiscence Membrane exposure
(GTR treated sites)
Suppuration Abscess formation Swelling Allergic reaction
A. Sculean et al.
1999a [56]
– 7/16 GTR sites (3 w) No No 7/16 EMD sites
8/16 GTR sites
(first w)
No
A. Sculean et al.
1999b [60]
– No No No – No
N. Donos et al.
2004 [62]
– 2/3 GTR sites (BM alone),
5/7 GTR sites (BM + EMD)
(first 2 w)
– No – No
P. Cortellini
et al. 2005 [57]
2/11 GTR sites (BM + BG), 1/7
GTR sites (BM alone) 1/10 EMD
sites (1–2 w)
– – – – –
A. Crea et al.
2008 [61]
3/20 GTR sites 2/19 EMD sites
(5–6 days)
– – No No No
V. Iorio-Siciliano
et al. 2011 [58]
– 3/20 GTR sites (5 w) – – – –
V. Iorio-Siciliano et al.
2014 [59]
– 4/20 GTR sites (1 w) – – – –
BM bioabsorbable membrane, BG bone graft, EMD enamel matrix derivate, GTR guided tissue regeneration, w week
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was registered only 3.1% in the EMD treated sites whereas
flap dehiscence/ membrane exposure was observed in the
22% of defects treated with GTR.
In all the remaining studies none of the others param-
eters evaluated (suppuration, abscess formation and/or
allergic reaction) were observed. In only one study [60]
the early wound healing was reported to be uneventful.
Healing outcomes associated to treatment characteristics
– Defect morphology
When 2 to 3-wall contained intrabony defects [56, 57,
61] were evaluated flap dehiscence/membrane exposure
was presented in 11/42 (26%) sites treated by GTR and
in 3/46 (6.5%) of sites treated with EMD. No dehiscence
was observed when non-contained intrabony defects
were treated with EMD (40 treated defects) [58, 59].
However, when GTR procedure was performed in these
defects dehiscence/membrane exposure was observed in
9/63 (14%) of the treated sites [57–59].
One of the study [60] – in which advanced intrabony
defects in teeth that were scheduled for extraction were
assessed, did not report any complication in the healing
process of neither group (EMD and GTR).
Finally, in the furcation GIII defects [62], 7/10 (70%)
of the GTR treated sites presented membrane exposure
while dehiscence was not observed in the EMD group (4
treated sites).
– Incision and flap design technique
When the incision/flap design was evaluated, membrane
exposure was observed in 14/33 (42.4%) of the defects
treated with GTR without any papilla preservation tech-
nique [56, 60, 62]. However, when SPPF or MPPT were
used [57–59, 61] flap dehiscence was registered in 3/29
(10.3%) of the defects treated with EMD [57, 61] and flap
dehiscence/ membrane exposure in 13/90 (14.4%) of sites
treated with GTR (Table 6).
– Biomaterials
In cases treated with GTR, flap dehiscence/membrane
exposure was found in 21/71 (30%) of the sites where
resorbable membranes have been used [56, 57, 59, 60, 62]
and in 6/52 (11.5%) of defects treated with non-resorbable
e-PTFE membranes [57, 58, 61].
– Post-surgical medication
In two of the studies [58, 59] in which no antibiotics
but only anti-inflammatory drugs were administered,
early post-surgical complications were observed in 7/40
(17.5%) of the GTR sites whereas no complications were
observed in the EMD treatment group.
When antibiotics were administered [56, 57, 60–62],
complications like membrane exposure/dehiscence and
swelling were observed in 21/83 (25%) of the GTR sites
and in 10/56 (17.8%) of the defects treated with EMD.
– Suture
In three studies [56, 60, 62] in which the suture was
removed after 14 days the percentage of sites with mem-
brane exposure/flap dehiscence in the GTR defects was
42.4% (14/33) whereas in the EMD group 25.9% (7/27)
of the sites presented post-surgical complications in
terms of swelling as registered in one study [56].
In the remaining studies [57–59, 61] with a shorter su-
ture removal time (7–10 days) 13.4% (16/119) of the treated
sites showed dehiscence/membrane exposure. Moreover,
when this was analysed separately for the treatment groups
it was found that the complications were reported in 14.4%
of the GTR group and 5% of the EMD sites.
In total, of 219 evaluated sites flap dehiscence /membrane
exposure was registered in 22% (27/123) of the defects
treated with GTR versus 3.1% (3/96) in the EMD group.
If all the parameters evaluated are grouped as post-surgi-
cal complications, complications were observed in 28/123
(22.8%) of the GTR sites and in 10/96 (10.4%) of the sites
treated with EMD.
Discussion
Wound closure is one of the most important factors in
obtaining successful clinical results, especially in regen-
eration procedures [18]. With this regard, the first
post-operative week has been considered critical for the
maintenance of wound stability [19].
Findings from human studies have indicated that EMD
may play a major role in periodontal wound healing in
terms of fewer post-surgical complications when compared
to GTR surgical techniques and improved healing of inci-
sions by promoting formation of blood vessels and collagen
fibers in the connective tissue [29]. Moreover, clinical stud-
ies have indicated that treatment with EMD positively influ-
ences periodontal wound healing after surgical treatment
[17]. However, another clinical study showed that the early
wound healing of periodontal flap-surgeries in the sites
treated with EMD was not different from control sites
which were treated by open flap debridement alone [63].
The present systematic review was performed to
evaluate whether or not the use of EMD in regenerative
surgical treatment of periodontal intrabony defects show
better results in terms of early wound healing when
compared to GTR treatment.
The primary outcome parameters were registered be-
tween one and six post-surgical weeks. In this regard, seven
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studies could be compared. Due to a strong heterogeneity
a meta-analysis could not be performed, but a descriptive
data analysis revealed clinically relevant findings.
First, the data suggest that there is no relevant difference
in the early wound healing outcomes between the two
treatments evaluated, since flap dehiscence was observed in
the 12% of the GTR treated sites and in the 10.3% of the
EMD treated sites [57, 61]. Second, other parameters as
suppuration, abscess and allergic reactions were not
reported in any of the studies. Swelling was reported in one
study [56] but with no difference between the two treat-
ment groups. However, membrane exposure was observed
in the 28.8% of the GTR treated sites in 5 studies [56, 58–
60, 62]. While this finding was reported in a considerable
number of times, the control group using EMD did not
show such undesired wound healing. In our reading the
phenomenon “membrane exposition” is strictly related to
flap dehiscence. A flap dehiscence may not necessarily
result always in a membrane exposure but if a membrane
exposure is present, it means that a dehiscence of the flap
has also occurred. Therefore, this parameter should not be
considered separately. Moreover, none of the studies in-
cluded reported both parameters. Dehiscence was evaluated
in only two of the studies [57, 61] while membrane expos-
ure in five of them [56, 58–60, 62]. Therefore, an analysis of
both parameters together could be useful.
If we consider this analysis and match the information
resulting of both parameters, we can observe that flap
dehiscence was registered in a minimal amount (3.1%) in
the EMD treated sites whereas flap dehiscence/ membrane
exposure was observed in the 22% of GTR treated defects.
This is in agreement with a previous multicentre study in
which more post-surgical complications following GTR
were observed as compared to sites treated with EMD [28].
According to everything mentioned above, we remain with
our null hypothesis neither confirmed nor rejected.
In second place, as complete primary wound closure
of the flap during early wound healing is a prerequisite
for the success of regenerative therapy [64], the follow-
ing factors should be considered [65]: 1) incision and
flap design techniques; 2) correct suture technique and
removal time; 3) adequate post-surgical controls and
maintenance therapy; 4) type of biomaterials used.
Incision and flap design techniques
It has been reported that the use of inter-dental tissue
preservation surgical techniques provides a better flap
stabilization [66]. It is important to note that in the three
studies [56, 60, 62] where intracrevicular incisions were
made without any interdental surgical preservation tech-
nique, membrane exposure was observed in almost half of
the GTR of the treated defects (42.4%); conversely, when
SPPF or MPPT were used [57–59, 61] flap dehiscence/
membrane exposure was registered in only 10.3% of the
EMD treated defects [57, 61] and in the 14.4% of the GTR
treated sites (Table 6).
Suture technique and removal time
Suturing is one of the most important factors related to
wound stability [67], especially during the first post-surgical
weeks when adherence of the flap to the underlying hard
tissues is only guaranteed by a thin blood clot that is
converting to fibrous and osseous tissue [68, 69]. In fact, in
regenerative procedures the suture is normally removed
after 10 to 14 days post-surgery [68, 70]. It has been dem-
onstrated that the use of thick sutures (4–0) and/or early
suture removal can result in dehiscences of the formerly
adapted flaps [71]. In the studies included in the present re-
view this was not explicitly reported, even in three studies
[56, 60, 62] in which the suture was removed at 14 days the
percentage of sites with membrane exposure was higher
(42.4%) as compared to studies where this time was shorter
(7–10 days), with only 13.4% of the treated sites with dehis-
cence/membrane exposure [57–59, 61] (Table 6).
Post-surgical indications and maintenance
The post-surgical controls and maintenance therapy have
also been evaluated in this article. In general, the first
follow-up visit was scheduled 1 week after surgery [72] and,
in regenerative therapies with membranes, the recall visits
turned out to be more frequent during the first 2–3 weeks,
when professional tooth cleaning was performed [67, 73].
In all evaluated studies the first post-surgical control was
performed at one post-surgical week and the recall visits
were indicated every 1 or 2 weeks for the first 6–8 weeks.
In one study [61] the first evaluation was made at 5 days
and, at this time, a wound dehiscence could be observed in
the 14% (5/39) of the treated sites. This aspect is of
paramount importance because early controls might help
to detect early complications as can be a small flap dehis-
cence without a membrane exposure. Moreover, the time
to resume hygiene oral procedures must be considered
since it has been reported that only after 4–5 weeks the flap
is completely reattached to teeth and bone [65, 68]. This
period was considered in all the studies and the oral
hygiene procedures were resumed between 4 to 6
post-surgical weeks (Table 6).
Biomaterials
It has been demonstrated that non-resorbable membranes
have a higher risk of exposure than resorbable membranes
in GTR procedures [74]. In the included studies, no such
effect was shown. Of 123 sites treated by GTR, in 71 re-
sorbable membranes were used and in 52 e-PTFE mem-
branes. Surprisingly, flap dehiscence/membrane exposure
was present in 30% of the sites treated with resorbable
membranes, whereas only in 11.5% sites with non resorba-
ble e-PTFE membranes (Table 6). Regarding this point, it is
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important to underline that in the selected studies 20 of
the 52 treated sites were 3-wall contained intrabony
defects. Studies [11, 75, 76] show a good prognosis when
these defect types are treated with others surgical
approaches or with resorbable membranes.
It is important to highlight the fact that, when all the
previous mentioned factors related with the early wound
healing were evaluated, the group treated with EMD
presented a lower percentage of sites with post-surgical
complications respect the GTR group. This could be re-
lated to the aforementioned properties of the EMD in
the wound healing [15, 31].
In fact, if both evaluated parameters (dehiscence and
membrane exposure) are considered as one kind of
post-surgical complications, complications were observed
less often after EMD procedures than after GTR proce-
dures. This is in agreement with the results observed in a
systematic review [15] and clinical studies [41] in which
more post-surgical complications following GTR than after
EMD application have been reported. In fact, in a multicen-
tre clinical trial [41]in which 75 patients were treated, it
was observed that all cases treated with GTR presented a
post-surgical complication, mostly membrane exposure,
while only 6% of EMD treated defects showed complica-
tions. This study was not included in the present revision
since smokers were also evaluated.
Another important parameter is the administration of
systemic medications and especially antibiotics after or
during the surgical procedures. While a few studies con-
cluded that better healing and less discomfort is observed
when antibiotics were given [77, 78], in many other studies
[79–82] the use of antibiotics was considered not neces-
sary. Although there is currently no consensus regarding
this aspect, this parameter was assessed in the present re-
view (Table 6) in order to avoid a possible bias but, given
that in all studies drugs and posology were vastly different,
establishing any conclusion from the given data seems in-
appropriate. However, it was observed that in two of the
studies [58, 59] in which antibiotics were not administered
but only anti-inflammatory drugs (Ibuprofen or Acet-
aminophen), the early post-surgical complications (17.5%
GTR group and 0% EMD group) were not more frequent
than in the studies with antibiotic administration. In fact,
the complications registered were even more frequent in
the “antibiotic group” [56, 57, 60–62], in which 25% of the
GTR and 17.8% of the EMD group presented membrane
exposure/dehiscence and/or swelling. This is coincident
with a previous clinical study [82] that evaluated the role of
antibiotics in preventing early post-operative complications
after periodontal surgical procedures. The evaluation was
performed 1, 2, 4, 7 days and 3months after surgery and 3
groups were evaluated (amoxicillin, doxycycline and no
antibiotics). The authors reported no differences in terms
of early complications between the three groups. They
concluded that performing the surgical procedures
following strict asepsis the prevalence of complications is
low. Accordingly, prophylactic antibiotic to prevent post-
operative complications was considered unnecessary.
Two important aspects related to the included studies
should be especially considered: first, the already mentioned
heterogeneity observed among all the studies and especially
for defect morphology and second the studies ‘quality.
With respect to the first point, one of the most notable
differences between the studies was the morphology of
the defects (Table 5). Although generally in all studies
intrabony defects were included, the spectrum ranged
from “advanced intrabony defects” (scheduled for extrac-
tion) over 3-wall defects, partially non-containing defects
and GIII furcation defects. However, a descriptive
analysis distinguishes the different types of defects with
respect to the individual treatment that was performed.
In fact, the defect morphology –related also with the sur-
gical approach and the biomaterials selected - strongly in-
fluences the results of the surgical procedures [11, 57, 75,
76]. Clinical success was reported when contained intrab-
ony defects were treated with EMD. In non-contained
intrabony defects, GTR procedures are more indicated [11,
75, 76] although it has been observed in a recent study
successful clinical results when non-contained intrabony
defects were treated with EMD [83].
In the present systematic review, when the 2–3 wall con-
tained intrabony defects were evaluated it was observed flap
dehiscence/membrane exposure in 26% of the sites treated
by GTR whereas flap dehiscence was observed in only 6.5%
of the sites treated with EMD [56, 57, 61]. Instead, in non-
contained defects [57–59] 14% of the GTR treated sites
showed membrane exposure while no post-surgical compli-
cations were observed in the EMD group.
Finally, in the study treating furcation III defects [62],
membrane exposure was observed in seven of the ten
treated sites (70%). This study was the only one that com-
pared EMD with either GTR or GTR+ EMD. When the
membrane exposure was assessed in the GTR groups 2
(67%, with GTR) of 3 and 5 (71%, with GTR + EMD) of 7
sites were find to show that. Although no meta-analysis
was performed due to the small power of the published
data it seems that EMD as an adjunct to GTR did not
provide an additional benefit in the treatment of furcation
GIII defects. At the final follow-up, the results also demon-
strated that only a partial closure of the furcation entrance
was achieved. This finding was in accordance with a previ-
ous clinical study [84] which could not be considered in
this review since smokers were included.
Regarding the quality of the included studies [34–36], the
present review included six RCTs and one non-randomized
clinical trial (a case-cohort study) comparing EMD and
GTR surgical procedures. The quality of the RCTs were
found to be moderate to low, considering that three studies
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showed a high risk of bias [59, 60, 62] and three studies an
unclear risk of bias [56, 58, 61] (Table 2). The only study re-
ported as non-RCT [57] resulted to have a low risk of bias
(i.e., the study is comparable to a well-performed random-
ized trial with regard to all the domains; Table 3). Further-
more, a potential bias regarding the funding sources has to
be considered. In concerning this matter there was only
one study included that was supported by external com-
panies that sponsored the different biomaterials used for
both study groups (EMD and GTR) [62], what rendered
the risk for bias rather low.
In the present systematic review, we decided to
exclude smokers to avoid possible bias considering that
smoking affects the wound healing process [85]. Indeed,
in a recent clinical study [86] in which the impact of
smoking status on the clinical outcomes after regenera-
tive surgical procedures were evaluated, the authors
concluded that in smoker patients wound healing quality
was significantly hampered when compared to non-
smokers. A dose-dependent effect of smoking was
observed with respect to the values of PD reduction and
CAL gain at 6 months with a tendency to lower values
in patients consuming 11–20 cigarettes/day than in
smokers from 1 to 10 cigarettes/day. Accordingly, even
light smokers were excluded from the present analysis.
Specifically assessing early wound healing outcomes,
there are no RCTs comparing EMD and GTR for the
treatment of intrabony defects. Most of the studies focus
however on the long-term clinical outcomes after 12
months [76]. In addition, in none of the studies included
in the present revision, early wound healing was evalu-
ated with any of the indices/systems already proposed in
the literature [23, 24, 86].
Within the present systematic review, no relevant differ-
ences in the early wound healing results between EMD and
GTR surgical treatment in periodontal intrabony defects
can be found, although - when a deeper and detailed evalu-
ation of the studies was performed - a tendency for better
early healing in the group treated with EMD seems evident.
Particularly, when the analysis was performed considering
the different defect types it was observed that both
contained and non-contained intrabony defects presented a
higher percentage of dehiscence/membrane exposure when
GTR treatment was performed. These findings however
should be interpreted with care given the heterogeneity and
the quality of the studies included. The higher risk for
dehiscence and membrane exposure in GTR procedures,
however, cannot be interpreted as general superiority of
EMD in the early wound healing of the treatment of intrab-
ony defects. In fact, when only flap dehiscence was analysed
the results observed were similar for both treatment groups
(12% GTR versus 10.3% EMD treated sites).
Therefore, future RCTs comparing EMD and GTR
surgical procedures in terms of early wound healing are
necessary to understand if EMD presents an additional
benefit in this regard. In order to render a quantitative
meta-analysis possible study designs should be standard-
ized to reduce heterogeneity and possible biases. More-
over, long-term studies that compare early wound healing
outcomes to the final results would allow to deepen the
insight into the effect of uneventfully early healing.
Finally, it is important to mention that the purpose of the
present systematic review is not to suggest the one or the
other treatment type. Clinically, the decision for/against
EMD/GTR is multifactorial [76] and depends especially on
the defect morphology. Furthermore, the number of sites
to be treated and their localization might be of relevance,
since multiple defects or defects difficult to reach might
easier and less expensively be treated with EMD due to a
quicker and easier application as compared to the GTR
protocol.
Conclusion
Due to the considerable heterogeneity of the published
studies, a clear beneficial effect of the EMD on the early
wound healing outcomes after surgical treatment of
periodontal intrabony defects cannot be confirmed.
Standardized RCT studies are needed in order to allow
for proper comparison of early wound healing after both
types of surgical approaches.
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